Abstract
When selecting a strategy for the delivery of drug-nucleic acid combinations many factors need to be considered. It is important to validate that the combination of multiple therapeutic agents in a single delivery system provides advantages over the simple administration of combined free drugs. The pharmacokinetics and biodistribution of delivery systems must be carefully studied to guarantee sufficient drug concentration at the tumor site and subsequently enhance treatment efficacy. A large variety of synthetic lipid- and polymer-based nanocarriers have been proposed and tested as delivery platforms for drug-nucleic acid combinations. The targeting of therapeutic agents at other tissues often requires systemic delivery, and a carrier suitable for clinical use is paramount. In this chapter we look at a number of RNAi-based strategies that have entered clinical trial as well as the new combination strategies and ways of improving combination effects that have been developed. Such combination strategies provide new insights into the molecular and cellular mechanisms underlying the effects of combination treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
